NFIB mediates BRN2 driven melanoma cell migration and invasion through regulation of EZH2 and MITF by Fane, Mitchell et al.
EBioMedicine 16 (2017) 63–75
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comResearch PaperNFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion
Through Regulation of EZH2 and MITFMitchell E. Fane a,b, Yash Chhabra a,b, David E.J. Hollingsworth a, Jacinta L. Simmons c, Loredana Spoerri d,
Tae Gyu Oh e, Jagat Chauhan f, Toby Chin a, Lachlan Harris a, Tracey J. Harvey a, George E.O. Muscat e,
Colin R. Goding f, Richard A Sturm g, Nikolas K. Haass d, Glen M. Boyle c, Michael Piper a,h, Aaron G. Smith b,g,⁎
a The School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia
b School of Biomedical Sciences, Institute of Health and Biomedical Innovation at the Translational Research Institute, Queensland University of Technology, Woolloongabba, QLD 4102, Australia
c Cancer Drug Mechanisms Group, Department of Cell and Molecular Biology, QIMR Berghofer Medical Research Institute, Herston, Queensland 4006, Australia
d The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, QLD, Australia
e Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia
f Ludwig Institute for Cancer Research, Nufﬁeld Department of Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK
g Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, QLD 4102, Australia
h Queensland Brain Institute, The University of Queensland, Brisbane, QLD 4072, Australia⁎ Corresponding author at: Dermatology Researc
Queensland, School of Medicine, Translational Research
Australia.
E-mail address: a260.smith@qut.edu.au (A.G. Smith).
http://dx.doi.org/10.1016/j.ebiom.2017.01.013
2352-3964/© 2017 Published by Elsevier B.V. This is an opa b s t r a c ta r t i c l e i n f oArticle history:
Received 18 October 2016
Received in revised form 23 December 2016
Accepted 9 January 2017
Available online 16 January 2017While invasion and metastasis of tumour cells are the principle factor responsible for cancer related deaths, the
mechanisms governing the process remain poorly deﬁned. Moreover, phenotypic divergence of sub-populations
of tumour cells is known to underpin alternative behaviors linked to tumour progression such as proliferation,
survival and invasion. In the context of melanoma, heterogeneity between two transcription factors, BRN2 and
MITF, has been associated with phenotypic switching between predominantly invasive and proliferative behav-
iors respectively. Epigenetic changes, in response to external cues, have been proposed to underpin this process,
however the mechanism by which the phenotypic switch occurs is unclear. Here we report the identiﬁcation of
the NFIB transcription factor as a novel downstream effector of BRN2 function in melanoma cells linked to the
migratory and invasive characteristics of these cells. Furthermore, the function of NFIB appears to drive an inva-
sive phenotype through an epigenetic mechanism achieved via the upregulation of the polycomb group protein
EZH2. A notable target of NFIBmediated up-regulation of EZH2 is decreasedMITF expression, which further pro-
motes a less proliferative,more invasive phenotype. Together our data reveal that NFIB has the ability to promote
dynamic changes in the chromatin state of melanoma cells to facilitate migration, invasion and metastasis.








The underlying genetic and phenotypic heterogeneity associated
with melanoma tumours has resulted in a limited range of therapeutic
options as the disease progresses towards metastasis (Goodall et al.,
2008; Quintana et al., 2010; Thurber et al., 2011). Such heterogeneity
is not only deﬁned in terms of mutations in tumour suppressor and
proto-oncogenes between patients, but is further seen in individual tu-
mour subpopulations that differ in terms of phenotypic characteristics
such as proliferation and invasion. This heterogeneity has previously
been explained by irreversible genetic models such as clonal evolutionh Centre, The University of
Institute, Brisbane, QLD 4102,
en access article under the CC BY-NC(Nowell, 1976) and the cancer stem cell model (Reya et al., 2001), but
much evidencenow suggests that the epigenetic andmolecular changes
associatedwith these phenotypes are highly reversible and switch in re-
sponse to changes in the tumour microenvironment (Hoek et al., 2008;
Thurber et al., 2011; Wellbrock and Arozarena, 2015).
MITF and BRN2 have been found to mark two distinct subpopula-
tions of cellswithinmelanoma tumours that drive opposingphenotypes
(Goodall et al., 2008; Wellbrock and Arozarena, 2015). MITF expressing
cell types are characterized as highly proliferative and more differenti-
ated, while BRN2 populations adopt a highly invasive, stem-cell like ap-
pearance (Goodall et al., 2008). While the idea of phenotype switching
and mutual exclusivity between these two cell types is debatable
(Chapman et al., 2014; Haass et al., 2014), it is clear that BRN2 drives
an invasive melanoma cell phenotype (Arozarena et al., 2011; Boyle et
al., 2011; Kobi et al., 2010). Despite this, very little is known about
downstream effector BRN2 targets that may drive this undifferentiated
migratory cell type.-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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transcription factors (NﬁA, NﬁB, NﬁC, and NﬁX) that play a large role in
the development of a number of organs systems such as the lung and
brain (Grunder et al., 2002; Harris et al., 2015; Hsu et al., 2011;
Steele-Perkins et al., 2005), and is upregulated in many epithelial type
cancers (Dooley et al., 2011; Moon et al., 2011). While the expression
of NFIB has not been reported in melanocytic cells, recent ﬁndings
have demonstrated that NFIB governs epithelial-melanocyte stem cell
behavior in a shared niche (Chang et al., 2013). Interestingly BRN2 has
been proposed to maintain a less differentiated, stem cell-like pheno-
type in melanoblasts and a subset of melanoma cells (Cook et al.,
2003; Cook and Sturm, 2008; Goodall et al., 2008). Accordingly, we
chose to examine the expression and function of NFIB in the context
of BRN2 function in primary melanocytic cells and melanoma cells to
determine if this transcription factor plays a role in BRN2mediated phe-
notype switching.
2. Materials and Methods
2.1. Ethics Statement
Animal studieswere performed in strict accordancewith the recom-
mendations in the Australian Code for the Care and Use of Animals for
Scientiﬁc Purposes 8th Edition (2013), of the National Health andMed-
ical Research Council of Australia. All protocols were reviewed and ap-
proved by the QIMR Berghofer Medical Research Institute Animal
Ethics Committee (QIMR-AEC). All micewere housed in a speciﬁc path-
ogen free (SPF) facility, with 12 h light/dark cycle and continual access
to food andwater.Melanoma biopsieswere collectedwith informed pa-
tient consent, under a protocol approved by the Queensland Institute of
Medical Research and Princess Alexandra Hospital Human Ethics Com-
mittees. The study was conducted according to the Declaration of Hel-
sinki Principles.
2.2. Cell Culture and Transfection Analysis
A2058, MM96L, HT144, A11, MM418.5c, and MM537 human mela-
noma cell lines were cultured in RPMI media supplemented with 5%
foetal bovine serum, 2mML-glutamine, and 5mg/ml penicillin/strepto-
mycin. QF humanmelanoblast cell strains (MB) were cultured as previ-
ously described (Cook et al., 2003). BRN2, MITF, and NFIB siRNA
transfection in human melanoma cell lines were performed in 6 well
dishes as previously described (Thurber et al., 2011). The melanoblast
to melanocyte (MC) morphology differentiation (MB:MC) was per-
formed as previously described (Cook et al., 2003). The EZH2 inhibitor
GSK343 (Sigma Aldrich) was dissolved in DMSO and was used at a con-
centration of 0.1 μM, 1 μMand10 μM. TetOff stable cellswere cultured in
100 ng/ml of doxycycline, which was removed at the start of experi-
ments to induce expression of the transgene. All three parental lines
testedwere treatedwith doxycycline at 100 ng/ml to test for any off tar-
get effects and did not show any difference in the basal levels of BRN2,
NFIB, EZH2, GAPDH or any other genes of interest (data not shown).
2.3. Melanoma Sphere/Spheroid Formation and Invasion Assays
A2058 parental, BRN2, MITF and a 50:50 co-culture of A2058-GFP
and A2058-BRN2 cell lineswere cultured asmelanoma spheres and sec-
tioned as previously described (Thurber et al., 2011). Melanoma spher-
oids were prepared as described (Beaumont et al., 2015; Smalley et al.,
2008; Spoerri et al., in press). Both sphere and spheroid models mimic
in vivo tumour architecture and microenvironment and are used for in-
vestigating growth, invasion and viability ofmelanoma cells (Beaumont
et al., 2014; Santiago-Walker et al., 2009). Melanoma spheroids were
formed using A2058 empty, BRN2, MITF and NFIB cells and invasion as-
says were performed as previously described (Haass et al., 2014). Im-
ages were quantiﬁed using Image J software (http://rsb.info.nih.gov/ij)to calculate the area covered by the invading cells relative to the spher-
oid and overall spheroid growth.
2.4. Western Blot
Western Blot analysis was performed using techniques described
previously (Cook et al., 2003). Immunoblots were probed using rabbit
monoclonal BRN2 antibody D2C1L (Cell Signaling #12137), rabbit
monoclonal NFIB antibody (Sigma Aldrich; HPA003956), rabbit mono-
clonal MITF D567V (Cell Signaling #12590), mouse monoclonal EZH2
(Active Motif #39639), and Rabbit monoclonal H3K27 tri-methyl
C36B11 (Cell Signaling #9733), with anti-GAPDH 6C5 (Santa Cruz
#sc-32233) used as a loading control.
2.5. Xenograft Studies
For tumourigenicity studies, 2.0 × 106 cells in 50 μl of RPMI-1640/
10% FCS were injected intra-dermally into each of two sites of ﬁve
ﬁve-week old male immunocompromised BALB/c Foxn1nu mice. All
mice were monitored daily and tumour volume measured at least
twice weekly, recorded using digital calipers and expressed as mm3 ac-
cording to the formula A × b × b × 0.5 where A the length and b the
measured breadth of the tumour. Mice were also assessed for clinical
signs according to a QIMR-AEC approved clinical score sheet for distress
during the period of the experiment to determinewhether tumour bur-
den was causing distress to the mice to a degree and to where they
should be euthanized.
2.6. Statistical Analysis
Densitometry analysis was performed on Western Blots to quantify
the size and intensity of the band relative to a control sample to give
overall fold change andwere normalized usingGAPDHas a loading con-
trol. Wound healing assays, luciferase activity, and invasion/spheroid
growth assays were analyzed using a two-way ANOVA with a Tukey's
post-hoc test, with data presented as the mean ± SEM. A one-way
ANOVA with Dunnett's multiple comparisons test was performed on
quantitative real time samples.
3. Results
3.1. BRN2 and NFIB Expression in Melanocytic Cells
The expression and function of the nuclear factor one (NFI) family of
transcription factors have not been reported previously in melanocytic
cells. Initially, we were interested in the potential role these genes
may play in the context of the BRN2-MITF expression axis that has
been proposed to drive melanoma progression. A2058 human melano-
ma cells engineered to over-express either BRN2 orMITFwere analyzed
by qRT-PCR for expression of all four members of the NFI gene family,
NFIA, NFIB, NFIC and NFIX (Fig. 1A–D). MITF overexpression was found
to have only a modest, non-signiﬁcant effect on the expression of
these genes at the transcript level when compared with empty vector
control cells. BRN2 overexpression induced a signiﬁcant decrease in
NFIA, NFIC, and NFIX (Fig. 1A, C, and D), but interestingly resulted in a
signiﬁcant increase in NFIB expression (Fig. 1B). Subsequently, we
chose to examine the expression of NFIB in primary humanmelanoblast
(MB) cells induced to differentiate into fully pigmentedmaturemelano-
cytes (MC) (Cook et al., 2003). Three independent MB cell lines derived
from neonatal human foreskin were cultured until conﬂuent and in-
duced to differentiate via treatment with conditioned media over a
5 day period, with protein lysates taken initially (day 0) and at 24 h in-
tervals following treatment (Cook et al., 2003). BRN2 and MITF protein
levels were found to be inversely correlated over the course of differen-
tiation, with BRN2 levels decreasing as differentiation progressed (Figs.
Fig. 1. NFIB expression correlates with BRN2 inmelanocytic and melanoma cells. (A–D) QPCR analysis on A2058melanoma cells following lentiviral transduction to produce stable over-
expression of MITF or BRN2, investigating NFIA, NFIB, NFIC, and NFIX expression. Data represented as fold change relative to the empty vector control and normalized to B2M gene. (E–F)
Western Blot analysis on neonatal foreskin-derived QF1236 and QF1566 primary human melanoblast cells induced to differentiate into pigmented melanocytes over a 5-day period.
Antibodies were used against BRN2, NFIB, MITF, and GAPDH. (G) Whole cell lysates from six human melanoma cell lines immunoblotted for NFIB, BRN2, and MITF. (H) ChIP-ChIP
analysis data (Kobi et al., 2010) in 501 Mel human melanoma cells investigating BRN2 binding to chromatin regions, reveals BRN2 binds to a 2Kb intronic region located upstream of
the NFIB promoter. *: P b 0.05, **: P b 0.01, ***: P b 0.001. Data representative of three independent experiments. Band expression intensity of Western Blots was normalized to the
ﬁrst lane (GAPDH used as a loading control) using ImageJ software and indicated below each blot. Data from (A–D) is represented as the mean ± SEM and analysed using a one-way
ANOVA with Dunnett's multiple comparisons test. See also Fig. S3.
65M.E. Fane et al. / EBioMedicine 16 (2017) 63–751E, F, and S3A). NFIB levels followed a similar trend, gradually decreas-
ing ten-fold as differentiation progressed (Figs. 1E, F, and S3A).
As BRN2 and MITF have been found to exhibit a predominantly in-
verse expression pattern in melanoma cells which promotes switching
between invasive/migratory and proliferative phenotypes (Goodall et
al., 2008; Hoek and Goding, 2010), we chose to examine the expression
of BRN2, MITF and NFIB proteins in six melanoma cell lines. Expression
levels were normalized to the MM418c5 line. NFIB expression was
found to be signiﬁcantly higher in four of the six lines (2.8–3.5 fold)
with considerably lower expression seen in theMM418c5 and A11mel-
anoma lines (Fig. 1G). Interestingly, low NFIB lines also expressed neg-
ligible BRN2 protein but highMITF levels (Fig. 1G, lanes 1–2).Moreover,
of the four lines expressing high NFIB levels, three lines (HT144, A2058
and MM96L) expressed high levels of BRN2 (Fig. 1G). MITF expression
in the NFIB high lines was generally lower than the MM418.c5 or A11
lines which have low NFIB expression. One line, MM537 expressed
high levels of NFIB despite negligible expression of either BRN2 or
MITF transcription factors (0.6 and 0.4 fold relative to MM418.c5
respectively).
Together this data suggests a relationship between NFIB and BRN2
expression in melanoma cells at both the protein and transcript levels.
To further explore this possibility we examined a published ChIP-chip
data set that examined BRN2 promoter/enhancer occupancy in
501Mel cells (Kobi et al., 2010). This analysis revealed enrichment of
BRN2 binding within the ﬁrst intron of the NFIB gene locus (Fig. 1H),further suggesting that BRN2may be able to directly bind NFIB and reg-
ulate its expression in melanoma cells.
3.2. BRN2 Regulates NFIB and EZH2 Expression In-vitro
To further investigate the potential relationship between NFIB and
BRN2, the effect of gain or loss of BRN2 expression in a number of differ-
ent melanoma cell lines was tested. Firstly, siRNA knockdown of BRN2
in high NFIB expressing lines (A2058, MM96L and HT144) produced a
considerable reduction in NFIB expression to levels of approximately
80% fold or less in A2058 and MM96L melanoma cells and a modest
but consistent reduction in the HT144 cells (20%, 40% and 80%) across
the three independent siRNA treatment groups (Fig. 2A). The epigenetic
modulator EZH2 was also investigated as it has recently been linked to
melanoma invasion and metastasis (Zingg et al., 2015), and has been
previously identiﬁed as a target of NFIB in neuronal cell lineages
(Piper et al., 2014). EZH2 expression was found to decrease in response
to BRN2 siRNA knockdown in all three melanoma cell lines, reduced to
levels of 0.4 fold or lower across all three lines tested compared to the
negative siRNA control cells (Fig. 2A).
Conversely, constitutive BRN2 overexpressionwas also performed in
these same cell lines and revealed a commensurate increase in both
NFIB (3.8, 3.7, 2.4 fold respectively) and EZH2 (2.5, 2.3, 2.6 fold respec-
tively) expression across all threemelanoma cell lines (Fig. 2B). Similar-
ly, doxycycline controlled up-regulation of BRN2 in these cells (TET-
Fig. 2. BRN2 positively regulates NFIB and EZH2 expression. (A) Cell lysates from A2058, MM96L, and HT144 human melanoma cells treated with three different siRNA directed against
BRN2 were analyzed by Western Blot with antibodies against BRN2, NFIB, EZH2, and GAPDH (B) Cell lysates from A2058, MM96L, and HT144 human melanoma cells treated with
lentivirus to create stable overexpression of BRN2 were analyzed by Western Blot with antibodies against BRN2, NFIB, EZH2, and GAPDH (C) Cell lysates from doxocycline-off
inducible BRN2 expressing A2058, MM96L, and HT144 cells treated with and without dox for 48 h were analyzed by Western Blot with antibodies against BRN2, NFIB, EZH2, and
GAPDH. (D) NFIB immunoﬂuorescence (red) on A2058 parental cells grown on coverslips and treated with siRNA directed against BRN2. DAPI used to stain cell nuclei. (E) NFIB
immunoﬂuorescence (red) on A2058 BRN2 over-expressing cells. DAPI used to stain cell nuclei. (F) Cell lysates from A2058 and MM96L melanoma cells stably over-expressing BRN2
were analyzed by Western Blot for H3K27 tri methylation status (EZH2 global methylation marker). Band expression intensity of Western Blots was normalized to the ﬁrst lane
(GAPDH used as a loading control) using ImageJ software and indicated below each blot. All data representative of three independent experiments.
66 M.E. Fane et al. / EBioMedicine 16 (2017) 63–75OFF) promoted a reciprocal increase in NFIB expression to levels of 3.7,
3.2, and 2.5 fold across all three lines (Fig. 2C). Increased or decreased
NFIB expression in response to BRN2 gain or loss of function was also
conﬁrmed using immunoﬂuorescence (Fig. 2D and E), furthersupporting a potential role for BRN2 in regulating the expression of
both genes.
As EZH2 induces Histone-H3 tri-methylation at Lysine 27 (H3-
K27me3) we analyzed our protein lysates for global changes in H3-
67M.E. Fane et al. / EBioMedicine 16 (2017) 63–75K27me3 levels to determine if BRN2 increased EZH2 levels correlate
with increased activity of the protein. It was found that H3-K27me3
levels increased to 3.7 fold in both A2058−BRN2 and MM96L−BRN2 cells
compared to the respective empty vector control lines (Fig. 2F).
3.3. Effect of Modulating MITF Expression on NFIB Expression in Melanoma
Cells
Similar knockdown and overexpression experiments targetingMITF
in these cell lines revealed an inverse effect on NFIB and EZH2 expres-
sion levels to that mediated by BRN2. Speciﬁcally, over-expression of
MITF was found to decrease both NFIB and EZH2 levels, while MITF
knock-down increased NFIB and EZH2, although its effect on NFIB levels
inMM96L andHT144 cell lineswere not as pronounced as those seen in
A2058’s (Fig. S4A and S4B). Furthermore, MITF over-expression in both
A2058 and MM96L cells resulted in a global reduction on H3-K27me3
levels (Fig. S4C).
3.4. BRN2 Regulates NFIB Expression Within 3D Melanoma Spheres
Melanoma spheres provide a useful in vitro 3D model of melanoma
to better recapitulate an in vivo tumour microenvironment and archi-
tecture (Fang et al., 2005). Moreover, spheres have been found to reca-
pitulate the BRN2-MITF heterogeneity observed in vivo in contrast to
that seen using 2D culture and some spheroid models (Thurber et al.,
2011). Melanoma spheres were generated using A2058−empty,
A2058−BRN2, or A2058−MITF stable cell lines. Analysis of empty spheres
reveals that BRN2 predominantly localizes in cell populations in the pe-
riphery, while MITF expression appears heterogeneous throughout the
sphere in A2058−empty cells (Fig. S7A). Similar patterns were detected
using the parental A2058 cells (data not shown). Co-staining of BRN2
and MITF reveals a large number of cells exclusively expressing either
BRN2 or MITF (Fig. S7A), whereas staining of A2058 cells grown as a
2D mono-layer predominately shows co-localization between the two
transcription factors in themajority of cells (Thurber et al., 2011).West-
ern Blot analysis of A2058−BRN2 and A2058−MITF spheres conﬁrms that
they are inversely regulated upon overexpression (Fig. S7B).
NFIB positive cells were found to exhibit a similar distribution to
BRN2 positive populations within the spheres (Fig. S7C) and were pre-
dominately localized in the periphery of parental spheres generated
using A2058−empty (Fig. S7C upper panel). Furthermore, A2058−BRN2
spheres resulted in an increase in NFIB positive cells, which were dis-
tributed evenly throughout the sphere (Fig. S7C, middle panel). The in-
crease in NFIB levels in the A2058−BRN2 spheres was also validated by
Western Blot analysis (Fig. S7C). Additionally, A2058−MITF overexpress-
ing spheres showed a slight decrease in NFIB protein expression (30%
reduction), with localization in the spheres now randomized through-
out much lower and more randomized throughout (Fig. S7C, lower
panel).
3.5. Both BRN2 and NFIB Drive a Highly Migratory Melanoma Cell
Phenotype
Wound-healing assayswere ﬁrst performed in BRN2 andMITF over-
expressing cells (Figs. 3F and S5A–C) and in cells treated with pooled
siRNA against BRN2 and MITF (Figs. 3E and S5D–F) to assess migration.
Quantiﬁcation of wound repopulation, shown below the respective im-
ages, reveals that BRN2 overexpression signiﬁcantly increased the cells
ability to migrate and ﬁll the scratch, while knockdown of BRN2 signif-
icantly impaired migration (Figs. 3E, 4F and S5). Conversely, the oppo-
site trend was observed for MITF where migration was signiﬁcantly
impaired by over-expression and enhanced by siRNA knock-down
(Figs. 3E, 4F, and S5). Modulation of NFIB expression induced a very
similar migration phenotype to BRN2 whereby a signiﬁcantly increased
migratory capacity was seen in response to over-expression of NFIB
within wound healing assays (Figs. 3H, S1B, S1D, S1F and S1H), whilesiRNA knock-down signiﬁcantly decreased melanoma cell migration
rates (Figs. 3G, S1A, S1C, S1E and S1G).
3.6. NFIB Directly Increases EZH2 Expression
To extend upon the ﬁnding that BRN2 drives NFIB expression, we
wanted to further determine if the up-regulation of EZH2 in response
to BRN2 over-expression was mediated by NFIB. Firstly, we conﬁrmed
that while siRNA knock-down of NFIB had a negligible effect on BRN2
expression, EZH2 levels were signiﬁcantly reduced in all lines tested
using three independent siRNAs targeting NFIB (Fig. 3A). Conversely,
over-expression of NFIB in A2058, MM96L (relatively high NFIB lines),
MM418.5c, and A11 cell lines (both found to express minimal endoge-
nous NFIB protein) induced a commensurate up-regulation in EZH2
(Figs. 3B and S3G). Notably, modulation of NFIB had a substantial in-
verse effect on MITF expression in these studies, with MITF levels in-
creasing or decreasing following NFIB knockdown or overexpression
respectively (Figs. 3A and 4B).
Next, the activity of an EZH2promoter-luciferase reporter (WT), or a
mutant version in which the NFIB consensus sites have been mutated
(Mut), was determined in the A2058 over-expression lines (empty,
MITF, BRN2 and NFIB). The immediate EZH2 promoter (WT)was signif-
icantly more active in cells over-expressing BRN2 (P b 0.0001) and NFIB
(P b 0.05) compared to the empty control cells (Fig. 3C). Interestingly,
mutation of a previously identiﬁed NFIB binding site in this region
(Piper et al., 2014) dramatically reduced cis-activity in all lines tested in-
cludingBRN2, suggesting that NFIB binding is important in driving EZH2
promoter driven expression within this region downstream of BRN2
(Fig. 3C). While activity of the mutant reporter was lower than the
WT in the BRN2 over-expressing cells, this reporter was considerably
more active in these cells when compared with the other stable cell
lines, suggesting BRN2 might also be able to regulate the activity of
this region independently of NFIB, either directly or indirectly.
To further assess whether NFIB mediated increases in EZH2 protein
levels also correlated with an increase in EZH2 activity, global levels of
the methylation marker H3-K27me3 were investigated via Western
Blot analysis and were found to increase in both A2058−NFIB and
MM96L−NFIB cells compared to the respective empty vector control
cells (Fig. 3D).
3.7. NFIB Negatively Regulates MITF Expression in Melanoma Cells
In addition to upregulating EZH2 expression when overexpressed,
modulation of NFIB levels had a striking effect on MITF expression
with a clear inverse relationship predominating (Figs. 3A, 4B and
S3G). To examine this effect further, a luciferase reporter driven by
the immediate 1.8 kb region extending immediately upstream of the
MITF-M transcriptional start site was transfected into A2058−empty,
A2058−BRN2 andA2058−NFIBmelanoma cell lines (Fig. S2E). The activity
of this region was found to be signiﬁcantly lower in both BRN2
(P b 0.001) and NFIB (P b 0.0001) over-expressing cells compared to
the empty control. Furthermore, the cis-activity of the MITF promoter
region was signiﬁcantly elevated to similar levels in all three lines
when cells were treatedwith the EZH2 inhibitor GSK343 at 1 μMduring
transfection (Fig. S2E).
3.8. NFIB Is Required for BRN2 Induced Cellular Migration Through an EZH2
Mediated Pathway
Our data suggests that NFIB functions as a downstream target of
BRN2, which then potentially acts to increase EZH2 expression and de-
crease MITF expression. To determine if NFIB is required for the in-
creased migration seen in melanoma cells over-expressing BRN2,
A2058−BRN2, MM96L−BRN2, and HT144−BRN2 cells were transfected
with siRNA pools targeting NFIB or BRN2 itself (Figs. 4A, 5B, S2A, S2B
and S2D). Wound healing assays were then performed on these cells
Fig. 3. NFIB manipulation increases migration and EZH2 expression and decreases MITF expression. (A) Cell lysates from A2058, MM96L, and HT144 humanmelanoma cells treated with
three different siRNA directed against NFIB were analyzed byWestern Blot with antibodies against BRN2, NFIB, EZH2, MITF, and GAPDH. (B) Cell lysates from A2058, MM96L, and HT144
human melanoma cells treated with lentivirus to create stable overexpression of NFIB were analyzed by Western Blot with antibodies against BRN2, NFIB, EZH2, MITF and GAPDH. (C)
A2058 stables for MITF, BRN2, NFIB, and empty control cells transfected with two luciferase reporter constructs; A wild type construct containing a region of the EZH2 promoter
containing the NFIB putative binding site (WT) and a mutant construct with the NFI binding site mutated out (Mut). Data represented as relative luciferase fold activity following
normalisation against the empty-Mut. (D) Cell lysates from stable NFIB overexpressing A2058 and MM96L melanoma cells were analyzed by Western Blot for H3K27 tri methylation
status (EZH2 global methylation marker). (E) Quantiﬁcation of wound healing assay performed on A2058 human melanoma cells treated with siRNA against BRN2, MITF or a
scrambled control 24 h prior to wound initiation. (F) Quantiﬁcation of wound healing assay performed in A2058 stable BRN2, MITF and empty control cells. (G) Quantiﬁcation of
wound healing assay performed in A2058 human melanoma cells treated with siRNA against BRN2, MITF or a scrambled control 24 h prior to commencement of the experiment. (H)
Quantiﬁcation of wound healing assay performed in A2058 stable NFIB and empty control cells. Data represented as the mean ± SEM. *: P b 0.05, ***: P b 0.001, ****: P b 0.0001. A
two-way ANOVA with a Tukey's post-hoc test was performed in (C) and (E–H). All data representative of three independent experiments. See also Figs. S1, S2, S3 and S5.
68 M.E. Fane et al. / EBioMedicine 16 (2017) 63–75and revealed, as expected, that siRNA mediated knock-down of BRN2
over-expression attenuated the elevated migratory capacity of these
cells. Similarly, NFIB knockdown in these cells also resulted in a signiﬁ-
cantly reduced migration rate similar to levels seen in the BRN2 knock-
down (Figs. 4A, 5B, S2A, S2B and S2D). Protein analysis of these cells
revealed that NFIB is also required for BRN2 driven up-regulation of
EZH2 expression, with EZH2 levels in A2058−BRN2 and MM96L−BRN2
cells falling to similar levels as that observed in the A2058−empty control
cells in response to both BRN2 and NFIB siRNA knock-down (Figs. 4C
and S2C). This data suggests that NFIB is driving increased melanoma
cell migration and increased expression of EZH2 downstream of BRN2.
EZH2 has previously been implicated in driving melanoma cell mi-
gration and invasion (Zingg et al., 2015). Accordingly the EZH2 inhibitor
GSK343was used to assess the contribution of EZH2 to NFIB drivenmel-
anoma cell migration in the A2058−NFIB and MM96L−NFIB cells. Stable
cells were treated with 1 μM of EZH2 inhibitor and migration was
assessed using wound-healing assays (Figs. 4D, 5E and S6B). Inhibition
of EZH2 through GSK343 treatment resulted in a signiﬁcant decrease
in melanoma cell migration in the A2058-empty MM96L−empty control
cells when compared with the vehicle (DMSO) control cells (Figs. 4D,
5E and S6B). Moreover, A2058−NFIB and MM96L−NFIB cells, previously
shown to have elevated migration rates, were also found to have a sig-
niﬁcantly reduced migration in to the wound when treated with theinhibitor (Figs. 4D, 5E and S6B). Protein expression analysis was also
performed and revealed that treatment with the inhibitor had little ef-
fect on NFIB or BRN2 expression in either cell line, however MITF ex-
pression increased in the A2058−empty control cells in response to
1 μM GSK343 compared to the vehicle treatment (1.9 fold). Moreover,
MITF levels thatwere previously decreased in A2058−NFIB cells were re-
stored following treatment with the EZH2 inhibitor (2.4 fold) (Fig. 5F).3.9. MITF Re-expression Blocks NFIB Driven Increased Migration
Our data suggests that increased melanoma cell migration in re-
sponse to elevated NFIB is in part achieved through EZH2 mediated
down-regulation of MITF expression. This contention was further ex-
plored by restoring MITF expression in A2058−NFIB and MM96L−NFIB
cells. The migratory capacity of both A2058/MM96L−empty and A2058/
MM96L−NFIB cells, transduced 48 h previously with an empty (control)
or MITF (MITF) expressing lentivirus, was determined (Figs. 4G, 5H and
S6A). A2058−empty and MM96L−empty control cells were found to have
a signiﬁcantly decreased migration rate when MITF levels were in-
creased by transient lentiviral treatment. Furthermore, the increased
migratory capacity of A2058−NFIB andM96L−empty cellswas signiﬁcant-
ly attenuated by lentiviral MITF expression and exhibited a migration
Fig. 4.NFIB drivesmigration downstream of BRN2 through interactionswith EZH2. (A–B) Lightphase images and quantiﬁcation ofwound healing assays performed in A2058 stable BRN2
cells treated with siRNA against BRN2, NFIB or a scrambled control 24 h prior to wound initiation (0 h), with images taken at 0, 24, and 48 h. (C) Cell lysates from A2058 BRN2 stable
melanoma cells treated with siRNA against BRN2, NFIB or a scrambled control were analyzed byWestern Blot with antibodies against BRN2, NFIB, EZH2, and GAPDH. (D-E) Lightphase
images and quantiﬁcation of wound healing assays performed in A2058 stable NFIB cells treated with EZH2 inhibitor GSK343 at 1 μM or a vehicle control (DMSO) 24 h prior to wound
inititation (0 h), with images taken at 0, 24, and 48 h. (F) Cell lysates from A2058 NFIB stable melanoma cells treated with GSK343 at 0.1 μM, 1 μM or a vehicle control (DMSO) were
analyzed by Western Blot with antibodies against BRN2, NFIB, EZH2, MITF and GAPDH. (G-H) Lightphase images and quantiﬁcation of wound healing assays performed in A2058
stable NFIB melanoma cells treated with MITF or empty control lentivirus 24 h prior to commencement of the experiment, with images taken at 0, 24, and 48 h. Data represented as
the mean ± SEM and analysed with two-way ANOVA with a Tukey's post hoc test. **: P b 0.01, ***: P b 0.001, ****: P b 0.0001. All data representative of three independent
experiments. Band expression intensity of Western Blots was normalized to the ﬁrst lane (GAPDH used as a loading control) using ImageJ software and indicated below each blot. See
also Figs. S2 and S6.
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Fig. 5.Overexpression of BRN2 decreasesmelanoma cell tumourigenicity but increases invasion. (A–B)2× 105 A2058humanmelanoma cellswith stable over-expression of empty control
orNFIBwere injected subcutaneously into the hindﬂanks ofﬁve 5-week oldmale immunocompromised BALB/c Foxn1numice. Three-dimensionalmeasurementwas performed two times
per week, with tumour volume expressed as mm3. (C) Analysis of 471 melanoma samples in the TCGA dataset comparing NFIB expression and its correlation with a previously reported
invasive gene signature (Verfaillie et al., 2015). Grey bars represent average expression of NFIB in each individual tumour, while the black line is a rank based on the average expression of
the invasive gene signature used for initial sorting of the samples from low invasive to high invasive phenotypes. The purple line represents a moving average of NFIB expression per 20
tumours. Linear regression analysis reveals a Spearman P-value = 3.553e−15 indicating a positive correlation between NFIB and invasiveness. (D) MM96L stable BRN2, MITF, NFIB, or
empty human melanoma cells grown on agarose to generate 3D non-adherent melanoma spheroids. Spheroids were embedded in a collagen-media mixture and left to grow over a
72 h time-frame, with light phase photographs taken every 24 h. (E) Spheroid invasion was calculated from (D) by determining the change in the area of the invading cells
disseminating away from the spheroid at 24 h time intervals relative to the 0 h timepoint. (F) The change in spheroid size was determined in (D) by measuring the change in area
occupied by the spheroid alone (not the invasive populations) at 0 h vs. 72 h. *: P b 0.001, **: P b 0.001 ****: P b 0.0001. A two-way ANOVA with Tukey's post hoc test was performed
on E–F. Changes in area occupied by invading cells and spheroid growth were calculated using ImageJ software. Data from (D–F) is representative of three independent experiments
and is represented as the mean ± SEM. See also Fig. S3.
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S6A).3.10. NFIB Overexpression Increases Invasion But Decreases
Tumourigenicity
A rheostat model for MITF has been proposed that argues that the
co-ordination of key tumourigenic activities such as initial tumour for-
mation through to subsequent progression and metastatic dissemina-
tion is intimately linked to MITF expression levels (Carreira et al.,
2006; Goding, 2011). To investigate the tumourigenic properties of
NFIB expressing cell lines, A2058−NFIB over-expressing humanmelano-
ma cells were injected into immune-compromised BALB/c Foxn1numice
in two different injection sites (left and right rear ﬂank), and were
culled once the ethical tumour burden was reached. Interestingly,
while the A2058−empty control cells were able to form tumours efﬁ-
ciently in 9/10 injection sites (Fig. 5A), A2058−NFIB cells failed to form
tumours (Fig. 5B). Protein analysis of these melanoma cell models
prior to injection conﬁrms that MITF has been drastically reduced in
these NFIB lines (Fig. S3H).In silico analysis of RNA-Seq data from 471 melanoma tumours
contained in the TCGA database revealed a strong correlation between
NFIB expression levels and an invasive gene signature (Fig. 5C). In this
analysis, data was sorted and ranked from low to high expression of a
previously reported invasive gene signature identiﬁed in melanoma tu-
mours and cell lines (Verfaillie et al., 2015) with the line of best ﬁt for
this expression signature represented by the black line (Fig. 5C).Within
this dataset, a grey bar represents level of NFIB expression for each indi-
vidual tumour, and the purple line represents a moving average of NFIB
expression per 20 melanomas across the sample set (Fig. 5C) with a
strong association between NFIB levels and expression of the invasive
gene set evident (Spearman correlation P= 3.553 × 10−15).
The effect of BRN2, MITF and NFIB over-expression inmelanoma cell
invasiveness was then determined using spheroids embedded in a col-
lagen matrix, with invasion monitored at 24 h time points over a 72 h
period (Fig. 5D). Quantiﬁcation of cellular invasion into the collagenma-
trix revealed a signiﬁcant increase in invasion of both BRN2 and NFIB
over-expressing cell lines when compared with the empty vector con-
trol, whereas MITF over-expressing cells displayed a signiﬁcantly im-
paired invasive capacity (Figs. 5D and 6E). A comparison of the overall
growth of these spheres at 0 and 72 h also reveals that NFIB and BRN2
Fig. 6.NFIB shows colocalisation with BRN2 inmelanoma tumours and shows increased expression in aggressive/metastatic melanomamodels. (A) Immunoﬂuorescence microscopy on
A2058 xenograft tumours surgically excised, formalin-ﬁxed, and embedded in parafﬁn. Tumours were sectioned at 5 μm thickness and antigen-retrieved before labelingwith BRN2 (red)
and NFIB (green) antibody. DAPI was used to stain nuclei. (B-C) Immunoﬂuorescence microscopy as described above on patient derived subcutaneous primary melanoma tumours and
Lymph node metastatic melanoma tumours. (D) Microarray analysis of melanoma clinical samples representing 31 primary melanomas and 52 melanoma metastases from a previously
published data set (Xu et al., 2008). Relative RNA expressionwas plotted and linear regression analysiswas performed investigating the relationship between BRN2 andNFIB expression in
metastatic samples. (E) Regression analysis on the above dataset looking at a correlation betweenMITF and NFIB expression inmetastatic tumours. (F) Analysis of relative NFIB expression
(log2 transformed) in 102 primary and 368metastatic tumours from the TCGA dataset. Data represented as a violin plot and analyzed using theMann-Whitney rank test. (G) Microarray
analysis of subcutaneous tumours or lung metastases from immunodeﬁcient mice injected subcutaneously or intravenously with a poorly-metastatic A375 melanoma cell line or with
highly-metastatic derivative cell lines from a previously published dataset (Xu et al., 2008). Relative NFIB RNA expression was investigated in three speciﬁc groups; Poorly metastatic
(PM), Subcutaneous tumours (SC), and the resultant lung metastases from the aforementioned subcutaneous tumours (LM). (H) Microarray analysis of relative NFIB expression (log2
transformed) in primary cutaneous melanomas derived from iMet (metastasis-capable) and iHRAS (non-metastatic) models from a previously published dataset (Scott et al., 2011). *:
P b 0.05, ***: P b 0.001. A one-way ANOVA with a Tukey's post-hoc test was performed on (H). Data is represented as the mean ± SEM. Scale bars in white represent 200 μm. See also
Figs. S3 and S6.
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MITF spheroids, suggesting a decrease in their proliferation rate (Fig.
5F).
3.11. BRN2 and NFIB Show Co-localisation in Primary and Metastatic Hu-
man Tumours and NFIB Expression Is Correlated With Aggressive
Melanoma
Previous studies have shown that BRN2marks a distinct subpopula-
tion of highly invasive cells locatedwithinmelanoma tumours (Goodall
et al., 2008; Pinner et al., 2009). Potential co-localisation of NFIB and
BRN2 in vivo was initially examined in xenograft tumours generated
in BALB/c Foxn1nu mice using the A2058, MM96L, and HT144 human
melanoma cell lines. Heterogeneous BRN2 and NFIB staining through-
out the tumour was detected across all three tumour lines with co-
localisation evident in most cells (Figs. 6A and S3D). Furthermore this
co-localisation was also observed in human melanoma tissue excised
from both primary and metastatic human tumours (Figs. 6B, 7C, S3E
and S3f). Interestingly, there appeared to be a greater proportion of
BRN2/NFIB positive cells in metastatic tumours when compared with
the primary samples (not quantiﬁed). To further investigate changes
in NFIB expression in human melanoma tumours, bio-informatic inter-
rogation of a previously published gene expressionmicro-array data-setthat analyzed RNA transcript levels of clinical melanoma samples
representing 31 primary melanomas and 52 metastatic tumours (Xu
et al., 2008) was performed. Linear regression analysis comparing the
expression proﬁles of our various genes of interest reveals that there
is a signiﬁcant positive correlation between BRN2 and NFIB expression
in humanmetastatic tumours (P b 0.0046; Fig. 6D). This analysis also re-
vealed a signiﬁcant inverse correlation between MITF and NFIB expres-
sion in metastatic tumour lines, with MITF levels decreasing as NFIB
levels increase (P b 0.0068; Fig. 6E). Interestingly, both correlations
were not signiﬁcantwhen analyzed in the primary human tumour sam-
ples (Fig. S3B and S3C). This same study also employed a Patient De-
rived Xenograft (PDX) based strategy to identify highly metastatic
tumour cells, whichwas then correlated with a metastatic gene expres-
sion signature using expression arrays (Xu et al., 2008). Tumours arising
in the PDX model allowed stratiﬁcation of tumours into non/poorly-
metastatic (PM) and highly metastatic tumours with the latter group
further sub-divided into samples taken from the sub-cutaneous tumour
(SC) or a subsequent lung metastasis arising from the primary tumour
(LM). Interrogation of the gene expression data set obtained from the
PM, SC and LM tumour populations, reveals that relative NFIB expres-
sion is increased in the highly metastatic tumours, both subcutaneous
(SC) and lung metastases (LM), when compared with the poorly meta-
static (PM) tumour group (Fig. 6G). Interestingly, lung metastases also
Fig. 7. BRN2 and NFIB colocalise with EZH2 populations in vivo. (A) Immunoﬂuorescence microscopy on A2058 xenograft tumours surgically excised, formalin-ﬁxed, and embedded in
parafﬁn. Tumours were sectioned at 5 μm thickness and antigen-retrieved before labeling with BRN2 (red) and EZH2 (green) antibody. DAPI was used to stain nuclei. (B–C)
Immunoﬂuorescence microscopy as described above on patient derived subcutaneous primary melanoma tumours and Lymph node metastatic melanoma tumours, labeled with BRN2
(red) and EZH2 (green). (D) Immunoﬂuorescence microscopy on A2058 xenograft tumours as described above, labeled with NFIB (red) and EZH2 (green) antibody. (E–F)
Immunoﬂuorescence microscopy as described above on patient derived subcutaneous primary melanoma tumours and Lymph node metastatic melanoma tumours, labeled with NFIB
(red) and EZH2 (green).
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neous tumours, suggesting thatNFIB expression is increased inmore ag-
gressive melanomas (Fig. 6G). Further interrogation of the TCGA
melanoma database, investigating primary (101) vs. metastatic (367)
derived patient tumours also reveals that relative NFIB expression is sig-
niﬁcantly increased in themetastatic tumour group (P b 0.001)(Fig. 6F)
and that there is a signiﬁcant correlation between BRN2 and NFIB ex-
pressionwithin both groups (Fig. S6C). Finally, interrogation of an inde-
pendent data set from an alternative xenograft study (Scott et al., 2011)
also demonstrated elevated NFIB levels in highly metastatic tumours
compared to the non-metastatic tumours (P b 0.05) (Fig. 6H).3.12. BRN2 and NFIB Colocalise With EZH2 Populations In Vivo
We have been able to dissect a BRN2-NFIB-EZH2 axis that drives a
highly invasive and migratory cell phenotype in vitro. To examine
whether BRN2 andNFIB expression is linkedwith EZH2 expressing pop-
ulations within tumours, colocalisation was examined in xenograft tu-
mours generated in BALB/c Foxn1nu mice as previously described using
A2058 melanoma cells. EZH2 was expressed heterogeneously through-
out each tumour, and showed distinct colocalisation with both BRN2
(Fig. 7A) and NFIB (Fig. 7D). Importantly, we ﬁnd that the largemajority
of EZH2 negative populations are also BRN2 and NFIB negative. This
colocalisation is also observed in primary human melanoma tumours
(Fig. 7B, D) and in metastatic human tumour samples (Fig. 7C, E).4. Discussion
Cellular heterogeneity has been linked to progression and therapeu-
tic resistance in numerous cancer types (Marusyk et al., 2012). In mela-
noma, heterogeneous expression of the BRN2 and MITF transcription
factors has been proposed to constitute a crucial switching mechanism
between invasive and proliferative phenotypes (Goodall et al., 2008;
Hoek et al., 2008; Hoek and Goding, 2010; Pinner et al., 2009;
Quintana et al., 2010; Thurber et al., 2011). MITF has been identiﬁed
as a crucial oncogene in melanoma, and accumulative evidence sup-
ports the hypothesis that its expression acts as a rheostat in controlling
cell cycle behavior and migration/invasion (Carreira et al., 2006;
Goding, 2011). In the context of phenotype switching, MITF expression
has been characterized as a driver of a highly proliferative, less invasive
cell state (Hoek et al., 2008; Vandamme and Berx, 2014). Conversely,
BRN2 has been implicated in promoting an invasive and less differenti-
ated state that is important in driving tumour progression towards me-
tastasis, however few downstream targets of BRN2 that facilitate this
phenotype have been identiﬁed (Arozarena et al., 2011; Boyle et al.,
2011; Pinner et al., 2009). Moreover, the mechanism that underpins
the switch between BRN2/MITF expression and associated phenotypes
remains poorly understood. Herewe report the regulation of expression
of the NFIB transcription factor by BRN2 in melanoma cells, which in
turn acts to increase cell migration and potentially invasion through
the positive and negative regulation of the epigenetic regulator EZH2
and MITF respectively.
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plored in melanoma, but has been characterized as an oncogene in var-
ious cancers and is frequently ampliﬁed in epithelial type cancers
(Chang et al., 2013;Dooley et al., 2011; Persson et al., 2009). Interesting-
ly, NFIB activity in the skin has been demonstrated to be a key regulator
of stem cell behavior in melanocytic stem cell niches (Chang et al.,
2013). In this context, it has been shown that knockout of NFIB within
this shared niche results in premature differentiation and proliferation
of melanocytic stem cells. Similarly, BRN2 expression has been shown
to maintain an undifferentiated melanoblast like cell phenotype during
melanocyte development (Cook et al., 2003, 2005). Using a cultured
human primary MB cell system, we observed high levels of BRN2 and
NFIB protein in melanoblast cells that decreased dramatically over the
course of differentiation into mature melanocytes. This role for BRN2
in facilitating a less differentiated phenotype has been observed in
sub-sets of cells within melanoma tumours that are known to be more
invasive (Pinner et al., 2009). The concept that cells undergo a process
of de-differentiation to amore stem-cell like phenotype to help enhance
metastasis has been well documented in various cancer models (Cheng
et al., 1999; Friedmann-Morvinski and Verma, 2014; Sell, 1993). Immu-
nostaining of NFIB within both mouse xenograft and human primary/
metastatic melanoma tumours shows clear co-localization with BRN2
expressing populations, indicating that NFIB expressionwithinmelano-
ma tumours is most likely linked with these more undifferentiated and
invasive cellular populations previously associated with BRN2 expres-
sion (Goodall et al., 2008; Pinner et al., 2009).
ChIP-ChIP experiments have detected BRN2 binding at the NFIB
locus in vivo using 501 Mel human melanoma cells (Kobi et al., 2010).
This observation, coupled with the reciprocal expression of NFIB in re-
sponse to gain or loss of BRN2 in 2D culture and 3Dmelanoma spheres,
and the co-expression seen in vivo suggests that there is likely a direct
regulation of NFIB by BRN2 in melanoma cells. MITF knockdownwithin
these models is shown to increase both NFIB and EZH2 expression.
While there has been no clear direct interaction between MITF and
these genes, previous studies have shown that knockdown of MITF
leads to an increase in BRN2 expression (Thurber et al., 2011), suggest-
ing that MITF may regulate NFIB and EZH2 indirectly through interac-
tions with BRN2. The increases seen in melanoma spheroid invasion in
both BRN2 and NFIB stable melanoma cells coupled with the loss of en-
hanced migratory capacity of BRN2 over-expressing cells when NFIB is
knocked down suggests that this factor is a pivotal component of driv-
ing this highly migratory/invasive melanoma cell phenotype within
BRN2 expressing populations. Crucially, recent reports from studies
using rodent models of Small Cell Lung Cancer (SCLC) have suggested
a vital role for NFIB in triggering invasive behavior that drivesmetastatic
spread of these tumours (Denny et al., 2016; Semenova et al., 2016). In
these models NFIB expression was found to be necessary and sufﬁcient
to supportmetastatic spread, an observation further supported by a cor-
relation between high NFIB expression and an advance metastatic tu-
mour grade in neuro-endocrine tumours from human patients
(Semenova et al., 2016). Our data presented here would suggest NFIB
is capable of propagating the acquisition of a more invasive phenotype
through broad changes in chromatin status, in large part by increasing
expression and function of the histone methyl-transferase enzyme
EZH2. Consistent with this idea, the pivotal role NFIB plays in the acqui-
sition of a metastatic phenotype in SCLC cells was identiﬁed in studies
initially aimed at characterizing genome wide alterations in chromatin
accessibility during metastatic progression of SCLC. The notable enrich-
ment of NFIB binding sites in these hyper-accessible regions of the ge-
nome ultimately revealed the role for NFIB in driving metastasis and
maintaining this permissive chromatin state (Denny et al., 2016).
Expression of the chromatin modifying enzyme EZH2 has been
shown to be directly controlled by NFIB in neuronal stem cells (Piper
et al., 2014). Interestingly, EZH2 has previously been characterized as
a potent driver of melanoma metastasis with high levels associated
with a poor patient prognosis (Bachmann et al., 2006; Fan et al., 2011;Luo et al., 2013; Zingg et al., 2015). Previous in silico screens searching
for high-afﬁnity NFI-binding sites within various polycomb repressive
complex gene sets identiﬁed two putative, highly conserved NFI-bind-
ing motifs in the basal promoter of EZH2 which was conﬁrmed by in
vitro and ChIP analyses (Piper et al., 2014). We were able to demon-
strate that EZH2 is up-regulated following both BRN2 and NFIB stable
overexpression in melanoma cells. EZH2 up-regulation is lost in
A2058−BRN2 and MM96L−BRN2 cells following NFIB siRNA knockdown,
suggesting that NFIB expression is crucial to this regulation. Further-
more, mutating the NFI-binding sites in our EZH2-promoter driven lu-
ciferase construct effectively blocked the increases seen in EZH2-
promoter driven expression. Interestingly, EZH2 expression has previ-
ous been linked with both increased growth and metastasis within tu-
mours, whereas our model is predicated on a slowly proliferative cell
phenotype. Unfortunately, NFIB cells failed to form tumours in xeno-
graft models, which did not allow us to assess tumour growth. While
melanoma cells often behave differently within the tumour microenvi-
ronment compared to cultured cells, it is possible that BRN2 and NFIB
regulate additional genes that counteract the growth phenotype that
might be anticipatedwith high EZH2expression. Recent intravital imag-
ing studies have found that EZH2marks a heterogeneous, highly motile
subpopulation of cellswithinmelanoma tumours that is thought to pro-
mote early stages of metastasis (Manning et al., 2015). This study links
these populations back to earlier intravital evidence showing that
BRN2 expression is required for melanoma cell motility within tumours
and dissemination into the blood stream during metastasis (Pinner et
al., 2009). Our data provides strong evidence showing that these hetero-
geneous EZH2 expressing tumour populations are also BRN2 and NFIB
positive and are likely mediated by BRN2 expression in an NFIB depen-
dent manner. While our data demonstrates that NFIB directly promotes
EZH2 expression downstream of BRN2, NFIB has been shown to repress
EZH2 in primary cortical cells in vitro and during cortical development
in-vivo (Piper et al., 2014) suggesting that cellular speciﬁcity and im-
portantly cellular context may determine if NFIB functions as a repres-
sor or activator at this locus. Computational predictions, coupled with
multiplex experimental analysis suggest that in most contexts, the NFI
family of transcription factors primarily act as transcriptional activators
(Pjanic et al., 2011).
MITF has previously been described as having both oncogenic and
tumour suppressor properties within melanoma (Hartman and Czyz,
2015; Levy et al., 2006). This idea is further perpetuated by the fact
thatwhile BRN2 andMITF have been shown to be expressed in twomu-
tually exclusive populations, BRN2 is able to both directly increase and
decrease MITF expression in a context speciﬁc manner (Goodall et al.,
2008; Thurber et al., 2011; Wellbrock et al., 2008). The phenotype-
switchingmodel of tumour progression dictates that these twomutual-
ly exclusive populations are able to selectively switch back and forth to
drive tumour growth through a predominately proliferative cellular
phenotype driven by MITF, and tumour metastasis by an invasive
BRN2 directed cellular population (Hoek et al., 2008; Hoek and
Goding, 2010). Evidence is emerging to suggest that this model is
more ﬂuid than previously thought, and that cells with considerably
lower invasive capacity are able to contribute to metastatic populations
through a cooperative invasion mechanism with highly invasive cells,
dependent on protease activity and ﬁbronectin deposition (Chapman
et al., 2014; Haass et al., 2014). Despite such other models emerging,
the link between BRN2 expression and invasiveness is well established
(Arozarena et al., 2011; Boyle et al., 2011; Kobi et al., 2010) which may
be achieved in large part due to the impact that BRN2 activity may have
on theMITF rheostat model, whereby invasion is driven by low levels of
MITF and proliferation is driven at higher levels (Carreira et al., 2006).
NFIB in this context would appear to function downstream of BRN2
and is shown to repress MITF expression, likely through the up-regula-
tion of EZH2 expression and activity. The tumourigenic assays per-
formed here show that NFIB overexpression impaired the ability of
these cells to form tumours in nudemice at the site of injection. Analysis
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levels are effectively silenced. In this context, stable over-expression of
NFIB limits the ability of these cells to upregulate vital components
such as MITF, that may be required for the cells to adapt to changes in
the local microenvironment in order to establish tumours. Analysis of
both proliferation and invasion within our spheroid assays clearly
show thatNFIB drives a slow cycling, highly invasive cellular phenotype.
While such a phenotypewould likely drive a highlymetastatic cell state,
it may not allow tumour formation at both primary and distal sites.
Thus, our results suggest that MITF levels regulated by NFIB down-
stream of BRN2 are key in tumour formation and growth. Importantly,
we are also able to show that NFIB likely regulates MITF by increasing
the levels of EZH2. As EZH2 acts to repress transcription via chromatin
methylation, such a mechanism suggests that NFIB is able to regulate
MITF in a way that is both dynamic and reversible, which would be a
key feature for switching between cell states that drives growth versus
metastasis. Speciﬁcally, NFIB expression and regulation within tumours
may be key in feeding into the MITF rheostat model downstream of
BRN2, whereby changes in BRN2 are able to dictate reversible changes
in MITF expression through NFIB and EZH2 to a level that will allow
for increased proliferation during formation, and increased migration/
invasionwhen undergoing a switch to amore EMT-like invasive pheno-
type during metastasis. Moreover, our analysis of NFIB function in mel-
anoma cells, together with recent evidence of NFIB as a powerful driver
of SCLCmetastasis suggest thatNFIBmay play a broader role inmetasta-
tic spread of other cancers. Importantly, these studies reveal that NFIB
has the ability to promote dynamic changes in the chromatin state of tu-
mour cells to facilitate migration, invasion, and metastasis. While our
study reveals the regulation of the EZH2 chromatin modifying enzyme
by NFIB is a key conduit of this effect in melanoma cells, it remains to
be determined if a similar epigenetic axis is governed via an NFIB-
EZH2 axis in other tumour types to drive invasion and metastasis.
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